Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer

Cancer Medicine

Volumn 4, Issue 12, 2015, Pages 1798-1808

  Kaur, Amanpreet ^a   Elzagheid, Adam ^a,b,c   Birkman, Eva Maria ^a   Avoranta, Tuulia ^a,d   Kytölä, Ville ^e   Korkeila, Eija ^a   Syrjänen, Kari ^f,g   Westermarck, Jukka ^a   Sundström, Jari ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF BENGHAZI   (Libyan Arab Jamahiriya)

^c Biotechnology Research Centre   (Libyan Arab Jamahiriya)

^d City of Helsinki   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f Biohit Oyj   (Finland)

^g BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Biomarker; colorectal cancer; PME 1; PP2A; survival; TCGA

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE B; PROTEIN PHOSPHATASE METHYLESTERASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CLINICAL FEATURE; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ENZYME INHIBITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL;

EID: 85006190522     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.541     Document Type: Article

References (32)

1. Naishadham, D., I. Lansdorp-Vogelaar, R. Siegel, V. Cokkinides, and A. Jemal. 2011. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol. Biomarkers Prev. 20:1296–1302.
2. de Gramont, A., B. Chibaudel, A. K. Larsen, C. Tournigand, and T. Andre. 2011. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin. Colorectal Cancer 10:218–226.
3. van de Velde, C. J., P. G. Boelens, J. M. Borras, J. W. Coebergh, A. Cervantes, L. Blomqvist, et al. 2014. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur. J. Cancer 50:1.e–e34.
4. Janssens, V., J. Goris, and C. Van Hoof. 2005. PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 15:34–41.
5. Westermarck, J., and W. C. Hahn. 2008. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 14:152–160.
6. Eichhorn, P. J., M. P. Creyghton, and R. Bernards. 2009. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 1795:1–15.
7. Haesen, D., W. Sents, E. Ivanova, C. Lambrecht, and V. Janssens. 2012. Cellular inhibitors of protein phosphatase PP2A in cancer. Biomed. Res. 23:SI 197–211.
8. Junttila, M. R., P. Puustinen, M. Niemela, R. Ahola, H. Arnold, T. Bottzauw, et al. 2007. CIP2A inhibits PP2A in human malignancies. Cell 130:51–62.
9. Puustinen, P., M. R. Junttila, S. Vanhatupa, A. A. Sablina, M. E. Hector, K. Teittinen, et al. 2009. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 69:2870–2877.
10. Khanna, A., J. E. Pimanda, and J. Westermarck. 2013. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res. 73:6548–6553.
11. Wiegering, A., C. Pfann, F. W. Uthe, C. Otto, L. Rycak, U. Mader, et al. 2013. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One 8:e75292.
12. Oaks, J. J., R. Santhanam, C. J. Walker, S. Roof, J. G. Harb, G. Ferenchak, et al. 2013. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 122:1923–1934.
13. Wandzioch, E., M. Pusey, A. Werda, S. Bail, A. Bhaskar, M. Nestor, et al. 2014. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells. Cancer Res. 74:4295–4305.
14. Li, J., S. Han, Z. Qian, X. Su, S. Fan, J. Fu, et al. 2014. Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target. Cancer Biol. Ther. 15:128–134.
15. Schneider, C. A., W. S. Rasband, and K. W. Eliceiri. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9:671–675.
16. Sobin, L. H., and C. Wittekind. 2002. Colon and rectum. Pp. 72–76 in L. H. Sobin and C. Wittekind, eds. TNM classification of malignant tumours, 6th ed. UICC. Wiley, New York, NY.
17. Glimelius, B., L. Pahlman, and A. Cervantes. 2010. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl 5):v82–v86.
18. Lipponen, P. K., and Y. Collan. 1992. Simple quantitation of immunohistochemical staining positivity in microscopy for histopathology routine. Acta Stereol. 11:125–132.
19. Korkeila, E., K. Talvinen, P. M. Jaakkola, H. Minn, K. Syrjanen, J. Sundstrom, et al. 2009. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br. J. Cancer 100:874–880.
20. Team, R. C. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
21. Therneau, T. M., and P. M. Grambsch. 2000. Modeling survival data: extending the Cox modeled. Springer, New York.
22. Tcgan, T. C. G. A. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337.
23. Zhu, J., J. Z. Sanborn, S. Benz, C. Szeto, F. Hsu, R. M. Kuhn, et al. 2009. The UCSC cancer genomics browser. Nat. Methods 6:239–240.
24. Cline, M. S., B. Craft, T. Swatloski, M. Goldman, S. Ma, D. Haussler, et al. 2013. Exploring TCGA pan-cancer data at the UCSC cancer genomics browser. Sci. Rep. 3:2652.
25. Stahlberg, A., N. Zoric, P. Aman, and M. Kubista. 2005. Quantitative real-time PCR for cancer detection: the lymphoma case. Expert Rev. Mol. Diagn. 5:221–230.
26. Marchionni, L., R. F. Wilson, S. S. Marinopoulos, A. C. Wolff, G. Parmigiani, E. B. Bass, et al. 2007. Impact of gene expression profiling tests on breast cancer outcomes. Evid. Rep. Technol. Assess. (Full Rep) 160:1–105.
27. Roberts, P. J., and C. J. Der. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310.
28. Gangarosa, L. M., N. Sizemore, R. Graves-Deal, S. M. Oldham, C. J. Der, and R. J. Coffey. 1997. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J. Biol. Chem. 272:18926–18931.
29. Tamaki, M., T. Goi, Y. Hirono, K. Katayama, and A. Yamaguchi. 2004. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncol. Rep. 11:655–659.
30. Wang, S. S., E. D. Esplin, J. L. Li, L. Huang, A. Gazdar, J. Minna, et al. 1998. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282:284–287.
31. Janssens, V., S. Longin, and J. Goris. 2008. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem. Sci. 33:113–121.
32. Tan, J., P. L. Lee, Z. Li, X. Jiang, Y. C. Lim, S. C. Hooi, et al. 2010. B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 18:459–471.